Orchestra BioMed Holdings, Inc.

About Orchestra BioMed Holdings, Inc.

Orchestra BioMed is a biomedical innovation company focused on accelerating high-impact medical technologies to patients through risk-reward sharing partnerships with leading medical device companies. Their partnership-enabled business model emphasizes strategic collaborations for global commercialization of developed products.

Products & Services

BackBeat Cardiac Neuromodulation Therapy™ (AVIM therapy):An investigational bioelectronic treatment for hypertension designed to provide immediate, substantial, and persistent blood pressure reduction while modulating autonomic nervous system responses.

Virtue® Sirolimus AngioInfusion™ Balloon (SAB):An investigational drug/device combination product for artery disease treatment, delivering an extended-release formulation of sirolimus during balloon angioplasty without coatings or permanent implants.

FreeHold Retractors:A product mentioned in the innovations section, though specific details about its purpose or application are not provided in the content.

AVIM therapy

Virtue SAB

Specialties

Hypertension Treatment Atherosclerotic Artery Disease Treatment Bioelectronic Therapies Drug/Device Combination Products Hypertension treatment Atherosclerotic artery disease treatment Risk-reward sharing partnerships with medical device companies

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Debt T: - FT: Debt	A: 20000000 MR: - FA: 20 million FAN: 20000000	D: 2026-05-06 FD: 2026-05-06	1 investors
2	RT: Royalty Financing T: - FT: Royalty Financing	A: 15000000 MR: - FA: $15 million FAN: 15000000	D: 2026-05-01 FD: 2026-05-01	2 investors
3	RT: Acquisition Proceeds T: - FT: Acquisition Proceeds	A: 21000000 MR: - FA: up to $21 million FAN: 21000000	D: 2026-01-12 FD: 2026-01-12	-
4	RT: Public Offering and Private Placement T: - FT: Public Offering and Private Placement	A: 111200000 MR: - FA: $111.2 million FAN: 111200000	D: 2025-08-05 FD: 2025-08-05	2 investors
5	RT: Public Offering T: - FT: Public Offering	A: 40000000 MR: - FA: 40 Million FAN: 40000000	D: 2025-08-01 FD: 2025-08-01	2 investors
6	RT: Strategic Investment (Equity and Convertible Debt) T: - FT: Strategic Investment (Equity and Convertible Debt)	A: 70000000 MR: - FA: $70 million FAN: 70000000	D: 2025-07-31 FD: 2025-07-31	2 investors

Debt Latest

2026-05-06

$20.0M

1 investor (Pro only)

Royalty Financing 2026-05-01

$15.0M

Acquisition Proceeds 2026-01-12

$21.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David P. Hochman

Chairman, Chief Executive Officer and Founder

D

Darren R. Sherman

President, Chief Operations Officer, Director and Founder

A

Andrew Taylor

Chief Financial Officer

W

William Baumbach, Ph.D.

Vice President, Scientific Affairs, Focal Therapies

Z

Ziv Belsky

Vice President, Research & Development, Bioelectronic Therapies

A

Amy Berman

Vice President, Clinical Operations

View 38 more team members with Pro

Unlock Full Team Directory

Recent News